The effect of antiviral therapy (AVT) on kidney function in liver transplantation (LT) recipients has not been well described despite known association of hepatitis C virus (HCV) infection with chronic kidney disease (CKD). We compared the incidence of CKD and end-stage renal disease ( 
Approximately, 20%-30% of them ultimately progress to cirrhosis over 30 years, (1) making it 1 of the primary indications for liver transplantation (LT) in developed countries. (2) There is increasing knowledge of the association between HCV infection and glomerular disease in both native kidneys and after kidney transplantation or LT. (3) HCV infection remains frequent in patients with chronic kidney disease (CKD). Its detrimental role in the progression to end-stage renal disease (ESRD) (2, (4) (5) (6) (7) (8) (9) (10) and on patient survival is well established. (11, 12) Infection with HCV is associated with CKD, progressive kidney function loss, and overall increased mortality. (2) In a recent meta-analysis involving nearly 3 million individuals where kidney function and HCV serological status was assessed, chronic HCV infection predicted a 51% increase in the risk of proteinuria and a 43% increase in the incidence of CKD. (12) CKD has become 1 of the leading causes of morbidity and death after LT. (13, 14) Although calcineurin inhibitor toxicity is typically considered a major contributor, other risk factors for CKD include perioperative acute kidney ORIGINAL ARTICLE | 1041 injury, type 2 diabetes mellitus (T2DM), hypertension (HTN), and chronic hepatitis C infection. (15) (16) (17) Recurrence of hepatitis C is universal after LT and potentially puts these patients at significantly increased risk of CKD. The advent of all-oral direct-acting antiviral (DAA) therapies has revolutionized LT, with HCV cure rates of more than 90% among treated patients. (18) The safety and tolerability of these DAA agents have been well established, and treatment has been expanded to the challenging pre-and post-LT cases. It is unclear whether treatment of hepatitis C in the peritransplant or posttransplant period will help prevent the decline in renal function and progression to CKD/ESRD in the LT recipients. Because the overwhelming majority of LT recipients develop CKD and consequently increase their risk of death when the estimated glomerular filtration rate (eGFR) is <30 mL/minute/1.73 m 2 , (13) it is of paramount importance to understand if antiviral therapy (AVT) for HCV can prevent the development and progression of CKD and improve outcomes. We examined the association of achieving sustained virological response (SVR) with AVT in HCV-infected LT recipients and kidney function over a 5-year follow-up. We hypothesized that achieving SVR is associated with preservation of kidney function, and a lower risk of declining eGFR and developing CKD/ESRD in LT recipients.
Patients and Methods

CoHort DEFiNitioN AND CoNFoUNDErS
The medical records of 1126 consecutive LT recipients between January 2006 and August 2015 were reviewed (Fig. 1 ). There were 446 patients with HCV cirrhosis who received LT. The following patients were excluded:
1. Graft loss within 6 months after LT. A total of 204 patients were included in the study for analysis.
Baseline demographic information including age at time of transplant, sex, race, presence of comorbidities such as HTN and T2DM at the time of transplant, lipid profile before LT, body mass index (BMI) before LT, and quantitative HCV RNA obtained using polymerase chain reaction (PCR) at the time of LT were obtained from chart review. Immunosuppression regimens were also collected up to the first 6 months after LT and were characterized in 2 groups defined as use of calcineurin inhibitors versus mammalian target of rapamycin (mTOR) inhibitors. We specifically included only the immunosuppression regimen for the first 6 months to categorize the groups considering our centers preference for using a steroid-free tacrolimus-based regimen for longterm primary immunosuppression unless there is baseline renal dysfunction in which case an early switch from tacrolimus to mTOR inhibitors as the primary immunosuppression is considered. Serum creatinine levels were noted at the following time points: 3 months after LT (defined as the baseline), 6 months after LT, 1 year after LT, 3 years after LT, and 5 years after LT. Only patients treated before December 31, 2016 were included to allow at least 12 months of follow-up. We used the last serum creatinine measurements prior to December 31, 2016 , in patients receiving DAA after this date. Serial eGFR was calculated using the Modification of Diet in Renal Disease study equation. (19) Approval from the University of Tennessee Health Sciences Center institutional review board (approval number 15-04062-XM) was obtained a priori.
PriMAry oUtCoMES ASSESSMENt
We compared CKD and ESRD based on treatment response to AVT. A binary endpoint of eGFR <30 mL/ minute/1.73 m 2 , which is clinically relevant, was chosen because it signifies severe CKD. CKD was defined as 2 eGFR levels <30 mL/minute/1.73 m 2 separated by ≥90 days, which means at least 2 time points during the follow-up period. ESRD was defined as the patient being on maintenance renal replacement therapy.
AVt rEGiMEN
Treatment regimens varied for patients between 2006 and 2015 and were categorized into interferon (IFN)-based therapy versus DAA therapy. The cohort included 102 patients within 1 year of LT, 57 patients within 1-3 years, and 45 patients beyond 3 years after LT. The distribution of the treatment regimen is shown in Table 1 . As noted, 89 (44%) received IFN without DAA, 8 (4%) received IFN with DAA, and 107 (52%) received a DAA-only regimen. The definition for SVR was based on American Association for the Study of Liver Diseases recommendations and has changed over the years based on the treatment regimen used (aviremia 12-24 weeks after completion of AVT based on treatment regimen used). (20) 
PoSttrANSPlANt iMMUNoSUPPrESSioN
Our institute uses a steroid-free immunosuppression protocol that consists of induction immunosuppression with rabbit antithymocyte globulin given at 3 mg/ kg in 2 divided doses of 1.5 mg/kg. (21, 22) The first induction dose is administered during the anhepatic phase, followed by the second dose on posttransplant day 2. Mycophenolate mofetil (MMF) at 1000 mg (or mycophenolic acid at 720 mg twice daily) 2 times a day for 3 months, starting on posttransplant day 1, is administered. MMF dose adjustments are made for gastrointestinal side effects and/or development of cytopenia. The initiation of tacrolimus is delayed for 3-7 days and started when serum creatinine is <2.0 mg/dL. An mTOR inhibitor is used instead of 
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tacrolimus if the recipient's serum creatinine remains over 2.0 mg/dL beyond posttransplant day 7. Goal trough levels for tacrolimus and sirolimus during the first 3 months postoperatively were 5-8 and 8-10 ng/ dL, respectively.
StAtiStiCAl CoNSiDErAtioNS
Statistical analyses were carried out using the Stata Statistical Software, version 13.1 (StataCorp, College Station, TX) and SAS, version 9.4 (SAS Institute Inc., Cary, NC). Descriptive statistics were calculated for all the key variables. Results are presented as percentages, mean (± standard deviation [SD]), or medians (interquartile range [IQR] ). Continuous variables were compared using Student t test or the Mann-Whitney U test, and categorical variables were analyzed with the chi-square test. In all statistical analyses, a 2-sided test was used, and the results were considered statistically significant if P was <0.05.
For multivariate analysis, logistic and Cox regressions were applied. Independent variables were included in the multivariate models based on theoretical considerations (variables associated with both SVR and CKD). Variance influence factors were used to indicate collinearity between independent variables.
Predictors for the presence of SVR were assessed using logistic regression analyses. The propensity score (PS) method was used to account for baseline differences arising from dissimilarities in clinical and demographic characteristics of patients with and without SVR. Variables associated with the achievement of SVR were identified using logistic regression and were used to calculate PSs. The following variables were included in the logistic regression model to create the PS: age at LT, sex, race/ethnicity, eGFR at baseline (3 months after transplantation), BMI, presence of HTN, presence of T2DM, degree of proteinuria, low-density lipoprotein (LDL) cholesterol level, and use of mTOR inhibitor or tacrolimus for immunosuppression after LT.
The association between SVR and incident CKD was assessed using unadjusted and PS-adjusted Cox proportional regression analysis and Kaplan-Meier plots with log-rank test. Proportional hazards assumptions were tested using scaled Schoenfeld residuals. As sensitivity analyses, we also performed time-dependent NOTE: Data are given as n (%), mean ± SD, or median (IQR). *The numbers do not add up as patients on both tacrolimus and mTOR were counted twice under their respective categories.
Cox regression analyses using the following strategy. Patients who never achieved SVR during the follow-up period were classified as members of the non-SVR risk set group. (The follow-up period was defined as time from transplantation to the censoring event). Patients who achieved SVR were classified as members of the SVR risk set group at the time of achieving SVR; however, for the time between transplantation and achievement of SVR, these patients were included in the non-SVR risk set group. As the exact time of ESRD initiation was not reliable, unadjusted and PS-adjusted logistic regression analysis was used to assess the association between SVR and ESRD.
The association between SVR and the slopes of eGFR versus time were examined in generalized linear mixed-effects models allowing for a random intercept and slope using the "XTMIXED" command in STATA. All patients had eGFR level at baseline, at 6 months, 1 year, 3 years, 5 years, and the last available before end of follow-up (December 31, 2017) after transplantation. The change in eGFR from 3 months posttransplant (baseline) until last eGFR data available after transplant and incident death (whichever occurred first) was studied in all transplant recipients whose baseline eGFR was >30 mL/minute/1.73 m 2 by using a 2-stage model formulation. In such a model, the level 1 change describes intraindividual changes in eGFR, and the level 2 model describes how the change coefficients differ across participants. The covariate of interest (SVR as the independent variable) is thus included in the level 2 models to explain interindividual differences in intraindividual change (slope). The effect of potential confounders on eGFR slopes was analyzed in a PS-adjusted mixed-effects model. We also assessed whether different treatment protocols (IFN versus DAA [+IFN]) could be an effect modifier in the association of SVR and outcomes. We also performed slopes of eGFR versus time analyses separately in recipients who received only IFN treatment and recipients who received DAA (+IFN) treatment as sensitivity analysis.
Results
BASEliNE CHArACtEriStiCS
Baseline characteristics of patients are presented in Table 1 . Patients are categorized into 2 cohorts: those who achieved SVR and those who did not achieve SVR. The mean age of LT recipients included in the study was 55 ± 7 years (range, 32-71 years). Three-fourths of patients included were Caucasian, n = 149 (73%), and the remainder were African American, n = 51 (25%); Hispanic, n = 3 (1.5%); and Asian, n = 1 (0.5%). In the cohert, 68% of the patients were males, 42% of patients had HTN, and 25% had T2DM at the time of LT; median eGFR at baseline (3 months after LT) was 67 mL/minute/1.73 m 2 (IQR, 51-81 mL/minute/1.73 m 2 ), and the average BMI was 28.3 ± 4.6 kg/m 2 . Of 204 patients, 145 patients achieved SVR, and 59 did not achieve SVR during the follow-up period. The mean eGFRs at baseline in the SVR and non-SVR groups were similar (69 ± 21 versus 65 ± 33 mL/minute/1.73 m 2 ; P = 0.27). A similar distribution of underlying comorbidities such as obesity, HTN, and T2DM was noted in both groups. In general, the baseline characteristics were similar between the 2 groups. Median HCV viral load at the time of transplant was similar but was more likely to be treated with DAAs. Proportions of patients receiving mTOR inhibitors and tacrolimus as primary immunosuppression were similar.
iNCiDENCE oF CKD
Of the 196 participants who remained after excluding 8 patients who had a baseline eGFR <30 mL/ minute/1.73 m 2 , 19 recipients developed CKD during the follow-up period (median, 2021 days; IQR, 1285-3054 days). The crude incident CKD rate was 16.5/1000 patient-years (95% confidence interval [CI], 10.5-20.8). The unadjusted incident CKD rate was significantly higher among patients who did not achieve SVR (crude incident CKD rate: 54.6/1000 patient-years; 95% CI, 30.2-98.6) compared with patients who achieved SVR (crude incident CKD rate: 8.4/1000 patient-years; 95% CI, 4.2-16.8; P < 0.001). Time to crude incident CKD was also higher in patients without SVR than virus-free recipients, as shown in the Kaplan-Meier plot (Fig. 2) . Table 2 shows the association between incident CKD and SVR. In unadjusted Cox proportional regression analyses, presence of SVR was associated with 88% lower risk of incident CKD (hazard ratio [HR], 0.12; 95% CI, 0.05-0.31). This association remained significant after adjustment for PS (HR, 0.11; 95% CI, 0.04-0.29). A similar trend was observed in our time-dependent sensitivity analysis. In unadjusted time-dependent Cox regression analyses, presence of SVR shows a trend toward a lower risk of incident CKD (HR, 0.42; 95% CI, 0.17-1.07). This association 
iNCiDENCE oF ESrD
Of the 204 participants, 23 recipients developed ESRD during the follow-up period. The frequency of patients with ESRD requiring dialysis among patients who achieved SVR was 5% (n = 7) compared with 27% (n = 16) among those who did not achieve SVR (P < 0.001). In unadjusted logistic regression analyses, the presence of SVR was associated with 86% lower risk of incident ESRD (odds ratio [OR], 0.14; 95% CI, 0.05-0.35). This association remains significant after adjustment for PS (OR, 0.18; 95% CI, 0.07-0.51; Table 2 ).
DECliNE oF KiDNEy FUNCtioN
In a multilevel mixed-effects model of change of eGFR, the overall slope of eGFR versus time was -1.15 mL/minute/1.73 m 2 /year (95% CI, -1.93 to -0.37). Figure 3A depicts the estimated slopes of eGFR in patients with and without SVR based on a 2-stage model of eGFR change. SVR was only included as a stage 2 variable. Patients with SVR had a less steep slope in eGFR (-0.60 mL/minute/1.73 m 2 /year; 95% CI, -1.50 to 0.30; P = 0.19; Table 2 ) than recipients without SVR (-2.53 mL/minute/1.73 m 2 /year; 95% CI, -3.99 to -1.07; P = 0.001; Table 2 ), and the differences in the slopes were statistically significant (P = 0.026). Figure 3B ,C shows the estimated slopes of eGFR in patients with and without SVR based on a 2-stage model of eGFR change in recipients who received only IFN treatment (Fig. 3B) and recipients who received DAA (+IFN) treatment (Fig. 3C ).
Discussion
In a cohort of LT recipients, we found that successful treatment of HCV infection had a clinically significant effect on lowering the risk of development of CKD based on eGFR <30 mL/minute/1.73 m 2 and ESRD over the median 5.5 years of follow-up after LT.
In the current analysis, we have noted that achieving SVR in LT recipients with recurrent HCV infection is associated with an 88% and 86% lower risk of developing CKD and ESRD, respectively. A prior study strictly including patients treated with IFN-based regimen reported that achieving SVR led to improved renal function in HCV-infected LT recipients with earlystage CKD. (23) A Taiwanese study in the nontransplant population concluded that SVR significantly improved renal outcomes. (24, 25) SVR has been associated with a decreased incidence of ESRD (24) as well as LT-related mortality and development of hepatocellular carcinoma. (26) (27) (28) As such, the beneficial effects of AVT may now be extended to its potential renal protective effect in the posttransplant setting. HCV infection induces kidney injury, mostly due to the formation of immune complexes and cryoglobulins, and possibly to a direct cytopathic effect. (29) Although the most common intrinsic mechanism of injury to the nephrons in chronic HCV has been linked to cryoglobulinemia-related immune complex deposition resulting in membranoproliferative glomerulonephritis, other glomerulonephropathies have also been implicated in the progressive decline of renal function. (30) (31) (32) Other investigators have found the presence of HCV particles or antigens in glomeruli or tubules of kidney biopsies. (33, 34) Implications of these findings on renal function are unclear and could have a hitherto undefined cytopathic effect. Additionally, up-regulation of inflammatory factors such as tumor necrosis factor α and interleukin 8 due to HCV infection as well as the core protein of HCV itself is associated with increased insulin resistance leading to renal cell proliferation and mesangial injury. (3, 35, 36) Several studies have linked insulin resistance with risk of developing CKD. (37, 38) We suspect that the beneficial effects on kidney function in LT recipients with successfully treated recurrent HCV stem from direct viral suppression and down-regulation of these inflammatory cytokines. Viral load decline as a consequence of treatment with novel DAAs in chronic HCV patients reduces serum levels of natural killer (NK) cell-stimulating cytokines and causes a correction of the altered NK cell phenotype observed in chronic HCV patients. (39) Potential effects of these changes and the relationship to renal function after achieving SVR with DAA treatment warrant further studies. Additionally, improved insulin resistance has been reported after successful treatment of HCV, potentially leading to a protective effect on renal function. (40) Antiviral treatment based on IFN and/ or ribavirin or triple AVT (pegylated IFN/ribavirin/ telaprevir or boceprevir) has been extensively used in the past with beneficial effects on kidney function in patients with HCV-related cryoglobulinemic glomerulonephritis. (41) Data on the beneficial 
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effects of DAAs in patients with HCV-associated cryoglobulinemic vasculitis are also emerging. (42) Development of renal dysfunction is not uncommon in LT recipients and has been associated with reduced survival and increased morbidity. (43) The prevalence of renal dysfunction varies and increases with longer follow-up. (44, 45) Previous studies have demonstrated impaired renal function in up to 70% of the patients or a 5-year risk of chronic renal failure after transplantation of a nonrenal organ of 7%-21%. (43) Although calcineurin inhibitor therapy has been largely considered to be the major factor responsible for the onset of CKD, several other risk factors have been associated with posttransplant CKD, including preexisting renal insufficiency; the duration of renal dysfunction in the pretransplant period; perioperative hemodynamic insults to the kidneys; the use of other nephrotoxic drugs; and the presence of HTN, diabetes, and HCV recurrence. (43, (45) (46) (47) (48) Except for the choice of immunosuppression, several factors which have been implicated in impaired renal function after LT cannot be modified. We have demonstrated that HCV is a potentially modifiable factor and achieving SVR can lead to a lower risk of decline in renal function and progression to ESRD. We noted that the estimated slopes of eGFR in patients with and without SVR based on a 2-stage model of eGFR change clearly shows that patients with SVR had significantly less steep slope than recipients without SVR, even after PS adjustment with time-dependent Cox regression analyses. This difference is even more dramatic in recipients who achieved SVR with DAA therapy. This supports the recommendation that eradication of HCV has a clinically significant beneficial effect in preventing decline in eGFR over time in the posttransplant period.
The current study includes patients both from the pre-DAA era as well as the DAA era. The development of DAA therapy for HCV has resulted in a remarkable improvement in SVR rates leading to viral eradication and cure, better tolerability, and decreased duration of treatment compared with IFN-and ribavirin-based therapy in the previous era. In the current analysis, we were able to find a difference in the renal outcome related to the treatment regimen used in the pre-DAA era and the DAA era. The effect was much stronger in the recipients that received DAA compared with IFN treatment. This result can be potentially explained by IFN contraindications including renal dysfunction, cytopenia, and potential risk for rejection. However, the use of IFN-based regimen could have been very restrictive, leading to a selection bias of patients being treated leading to progressive decline in renal function. This result needs to be interpreted with caution as the number of events was very low in the subgroup analysis. Further studies are needed to confirm or reject our results. Nevertheless, our result confirms the strong positive effect of DAAs in HCV-infected LT recipients in preventing decline in renal function by achieving SVR.
The current study has several limitations. Retrospective review of medical records likely underestimates the true prevalence and severity of CKD as the reliability of eGFR in LT patients can be questionable due to the fact that this population represents a dynamic cohort whose clinical course is marred by frequent changes in renal function. We have tried to address this using a binary metric (CKD based on eGFR <30 mL/minute/1.73 m 2 and ESRD). The selection criteria of LT recipients are center-specific and can potentially introduce a bias, which may limit wider applicability to other centers. Additionally, our center uses a steroid-free protocol with utilization of tacrolimus as the primary immunosuppression. Tacrolimus can have a potential effect in decline in renal function. Nevertheless, we expect the effect of immunosuppression on renal function is expected to be similar in both the SVR and the non-SVR group. Additionally, the sample size consists of patients treated with several different regimens, and the potential effect of a treatment regimen in inducing CKD was not evaluated in the current analysis. Despite these limitations, the study has several strengths, including a reasonable sample size of LT recipients with HCV infection. Also, a single-center analysis does provide some clarity to certain variables that may not be captured in large registries. Additionally, this is the first study that demonstrates HCV is a potentially modifiable risk factor for preventing decline in renal dysfunction after LT, and as such emphasizes a consideration for early institution of AVT for recurrent HCV after LT.
We conclude that LT recipients with chronic HCV infection achieving SVR can have a lower risk of developing progressive worsening of CKD and progression to ESRD independent of the AVT therapy used. The results of the current study should be validated in larger prospective, randomized controlled studies.
